Katherine P. Lett

Senior Counsel
Norton Rose Fulbright US LLP

United States
T:+1 214 855 8340
United States
T:+1 214 855 8340
Katherine P. Lett

Katherine P. Lett



Kathy Lett represents corporations and individuals in high profile personal injury and commercial litigation in state and federal courts throughout the country. Kathy has over 20 years experience defending pharmaceutical and medical device companies in multi-district and multi-plaintiff cases, as well in individual claimant litigation, with an emphasis on fact and expert witness preparation, risk assessments and trial strategy.  

Professional experience

Expand all Collapse all

JD, with honors, The University of Texas School of Law, 1998
BBA, magna cum laude, Texas A&M University, 1995

While attending law school, Kathy was a notes editor of The Review of Litigation. She was also a member of the Legal Research Board, the Board of Advocates and the Order of the Coif. She was admitted to practice law in Texas in 1998. Kathy is also admitted to practice in the Northern, Eastern, Western and Southern Districts of Texas.

  • Texas State Bar

Recent, significant experience includes:

  • Representing national franchisor in CPR arbitration of dispute with franchisee 
  • Represented leading dental equipment manufacturer and distributor in antitrust matter involving alleged vertical monopoly
  • Representing major pharmaceutical company in multiple economic loss cases involving alleged RICO violations, consumer fraud, consumer protection and subrogation claims brought by insurers, State AGs and Native American Tribes
  • Member of national drug safety team representing international pharmaceutical company in nationwide mass tort involving its proton pump inhibitors
  • Served on national team for an international medical device manufacturer in nationwide litigation involving its female pelvic mesh product; involved in litigation management, case strategy and discovery
  • Served on national team for leading pharmaceutical company in a large mass tort matter involving its diabetes medication; involved in strategy, discovery, witness preparation and multiple trials  
  • Successfully implemented a national settlement program for a leading life sciences company in connection with its medical product; ensured appropriate, defensible releases executed in hundreds of complex settlements spanning plaintiffs in over 40 states and several foreign countries
  • Represented medical device company in numerous matters involving employee violations of non-compete and non-solicitation agreements and unfair competition claims
  • Obtained temporary restraining orders, temporary injunctions and receivers for clients in commercial mortgage-backed securities litigation
  • Represented restaurant company in multi-state landlord-tenant disputes
  • Recipient, Global Inclusion Award, Norton Rose Fulbright, 2019
  • Drug and Device Caselaw Update, Moderator, IADC Webinar, May 2020
  • Capitalizing on Opportunities Created by Litigation, IADC Annual Meeting, Lisbon, Portugal, July 2018
  • Medical Tort Implications of Chapter 82 of the Texas Civil Practice and Remedies Code, Texas Bar CLE Advanced Medical Torts Course, May 10, 2017
  • State Bar of Texas
  • Dallas Bar Association
  • International Association of Defense Counsel
    • Vice Chair of Membership - Drug, Device & Biotechnology Committee (2021 to Present) 
    • Vice Chair of Communications - Drug, Device & Biotechnology Committee (2019 to 2021)
  • University of North Texas College of Law - Affiliate Professor
    • Practice Foundations II: Negotiations and Conflict Resolution (Fall 2018)
    • Practice Foundations II: Conflict Resolution, Mediation and Arbitration (Fall 2017)
    • Practice Foundations I: Interviewing and Counseling (Fall 2015)
  • Epilepsy Foundation of Texas
    • Secretary of State Board (2019 to 2020)
    • Vice President of Dallas/Fort Worth Board (2021 to Present)
  • Dallas Office Women Attorneys
    • Chairperson (2018 to 2021)
  • Preston Hollow Presbyterian Church
    • Ruling Elder (2018 to 2021)